📰 Sinomab Bioscience News
Sinomab Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sinomab Bioscience. Real-time updates on events, politics, business and more.
April 27, 2023
<p>HONG KONG SAR - <a href="https://www.media-outreach.com/">Media OutReach</a> - 26 April 2023 - A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - <b>SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company")</b>, is pleased to announce that Phase III clinical trial of SinoMabs flagship...
December 19, 2022
HONG KONG, Dec 19, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Company was awarded the "Most Valuable Pharmaceutical and...
November 4, 2022
HONG KONG, Nov 4, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical
September 26, 2022
Everest Medicines has received approval for a phase 1b study of EVER001 for the treatment of glomerular diseases.
September 26, 2022
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing...
November 3, 2021
Panellists say Hong Kong excels in biotech research, but needs to attract more talent and reassess its regulatory strategy Prenetics shows the future of healthcare is intertwined with that of biotech, as they display their new at-home rapid detection system for infectious diseases
September 17, 2021
Collaboration consolidates Everest's leadership in the renal space Everest Medicines will pay Sinovent and SinoMab USD $12 million in upfront and up to $549 million in total development, regulatory, and commercial milestone payments SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest") announced today that it has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals...
September 16, 2021
/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest") announced today that it has entered into an exclusive licensing agreement with Suzhou Sinovent...